AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Lysozyme C

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P61626

UPID:

LYSC_HUMAN

Alternative names:

1,4-beta-N-acetylmuramidase C

Alternative UPACC:

P61626; P00695; Q13170; Q9UCF8

Background:

Lysozyme C, also known as 1,4-beta-N-acetylmuramidase C, plays a crucial role in the body's defense mechanism. Its primary function is bacteriolytic, breaking down bacterial cell walls, particularly in association with the monocyte-macrophage system. This enhances the activity of immune agents, showcasing its vital role in the immune response.

Therapeutic significance:

Amyloidosis 8, a hereditary generalized amyloidosis, is linked to Lysozyme C. This disease features extensive visceral amyloid deposits and renal amyloidosis, leading to nephrotic syndrome, among other symptoms. Understanding the role of Lysozyme C could open doors to potential therapeutic strategies for treating Amyloidosis 8 and improving patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.